Publications

BibTex format

@article{Warwick:2015:10.1186/s12916-015-0328-1,
author = {Warwick, J and Falaschetti, E and Rockwood, K and Mitnitski, A and Thijs, LB and Beckett, NS and Bulpitt, CJB and Peters, RM},
doi = {10.1186/s12916-015-0328-1},
journal = {BMC Medicine},
title = {No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: An investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over},
url = {http://dx.doi.org/10.1186/s12916-015-0328-1},
volume = {13},
year = {2015}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Treatment for hypertension with antihypertensive medication has been shown to reduce stroke, cardiovascular events, and mortality in older adults, but there is concern that such treatment may not be appropriate in frailer older adults. To investigate whether there is an interaction between effect of treatment for hypertension and frailty in older adults, we calculated the frailty index (FI) for all available participants from the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over, and obtained frailty adjusted estimates of the effect of treatment with antihypertensive medication on risk of stroke, cardiovascular events, and mortality. Methods: Participants in HYVET were randomised 1:1 to active treatment with indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg or to matching placebo. Data relating to blood pressure, comorbidities, cognitive function, depression, and quality of life were collected at entry into the study and at subsequent follow-up visits. The FI was calculated at entry, based on 60 potential deficits. The distribution of FI was similar to that seen in population studies of adults aged 80 years and above (median FI, 0.17; IQR, 0.11-0.24). Cox regression was used to assess the impact of FI at entry to the study on subsequent risk of stroke, total mortality, and cardiovascular events. Models were stratified by region of recruitment and adjusted for sex and age at entry. Extending these models to include a term for a possible interaction between treatment for hypertension and FI provided a formula for the treatment effect as a function of FI. For all three models, the point estimates of the hazard ratios for the treatment effect decreased as FI increased, although to varying degrees and with varying certainty. Results: We found no evidence of an interaction between effect of treatment for hypertension and frailty as me
AU  - Warwick,J
AU  - Falaschetti,E
AU  - Rockwood,K
AU  - Mitnitski,A
AU  - Thijs,LB
AU  - Beckett,NS
AU  - Bulpitt,CJB
AU  - Peters,RM
DO  - 10.1186/s12916-015-0328-1
PY  - 2015///
SN  - 1741-7015
TI  - No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: An investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over
T2  - BMC Medicine
UR  - http://dx.doi.org/10.1186/s12916-015-0328-1
UR  - http://hdl.handle.net/10044/1/25783
VL  - 13
ER  -

Download

MsEmanuelaFalaschetti

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)